1h Free Analyst Time
Diabetic Macular Edema - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2020, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 18, 15, 4, 53 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionDiabetic Macular Edema - Overview
Diabetic Macular Edema - Therapeutics Development
Diabetic Macular Edema - Therapeutics Assessment
Diabetic Macular Edema - Companies Involved in Therapeutics Development
Diabetic Macular Edema - Drug Profiles
Diabetic Macular Edema - Dormant Projects
Diabetic Macular Edema - Discontinued Products
Diabetic Macular Edema - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Diabetic Macular Edema, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..3), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Products under Development by Companies, H2 2020 (Contd..3), H2 2020
- Products under Development by Companies, H2 2020 (Contd..4), H2 2020
- Products under Development by Companies, H2 2020 (Contd..5), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Diabetic Macular Edema - Pipeline by 3SBio Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Abpro Corp, H2 2020
- Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Adverum Biotechnologies Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Allegro Ophthalmics LLC, H2 2020
- Diabetic Macular Edema - Pipeline by Allergan Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Allgenesis Biotherapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Apexian Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Ascentage Pharma Group International, H2 2020
- Diabetic Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Ashvattha Therapeutics LLC, H2 2020
- Diabetic Macular Edema - Pipeline by BetaStem Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Bio-Thera Solutions Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Cell Care Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Celon Pharma SA, H2 2020
- Diabetic Macular Edema - Pipeline by Chiome Bioscience Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Drive Therapeutics LLC, H2 2020
- Diabetic Macular Edema - Pipeline by Elasmogen Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Eleusis Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Everglades Biopharma LLC, H2 2020
- Diabetic Macular Edema - Pipeline by Exonate Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by EyeGene Inc, H2 2020
- Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Formycon AG, H2 2020
- Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2020
- Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H2 2020
- Diabetic Macular Edema - Pipeline by Graybug Vision Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, H2 2020
- Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Kodiak Sciences Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Kowa Co Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Kubota Vision Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Kuur Therapeutics Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Luye Pharma Group Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Mabion SA, H2 2020
- Diabetic Macular Edema - Pipeline by Momenta Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by NeuMedics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Novartis AG, H2 2020
- Diabetic Macular Edema - Pipeline by Novelty Nobility Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Noveome Biotherapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by OccuRx Pty Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Ocugen Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Oculis SA, H2 2020
- Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Opthea Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Outlook Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Oxurion NV, H2 2020
- Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Phanes Therapeutics Inc, H2 2020
- Diabetic Macular Edema - Pipeline by PharmAbcine Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Pleryon Therapeutics Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Profarma, H2 2020
- Diabetic Macular Edema - Pipeline by Protheragen Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
- Diabetic Macular Edema - Pipeline by RemeGen Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Rezolute Inc, H2 2020
- Diabetic Macular Edema - Pipeline by RiniSight Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Ripple therapeutics Corp, H2 2020
- Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2020
- Diabetic Macular Edema - Pipeline by Semathera Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2020
- Diabetic Macular Edema - Pipeline by Suzhou Stainwei Biotech Inc, H2 2020
- Diabetic Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H2 2020
- Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2020
- Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2020
- Diabetic Macular Edema - Pipeline by YD Life Science Co, H2 2020
- Diabetic Macular Edema - Dormant Projects, H2 2020
- Diabetic Macular Edema - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Diabetic Macular Edema - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Diabetic Macular Edema - Dormant Projects, H2 2020 (Contd..3), H2 2020
- Diabetic Macular Edema - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Diabetic Macular Edema, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Abpro Corp
- Aciont Inc
- Adverum Biotechnologies Inc
- Aerie Pharmaceuticals Inc
- Aerpio Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allegro Ophthalmics LLC
- Allergan Ltd
- Allgenesis Biotherapeutics Inc
- Ampio Pharmaceuticals Inc
- Apexian Pharmaceuticals Inc
- Araim Pharmaceuticals Inc
- Ascentage Pharma Group International
- AsclepiX Therapeutics Inc
- Ashvattha Therapeutics LLC
- BetaStem Therapeutics Inc
- Bio-Thera Solutions Ltd
- Cell Care Therapeutics Inc
- Celon Pharma SA
- Chiome Bioscience Inc
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- Drive Therapeutics LLC
- Elasmogen Ltd
- Eleusis Ltd
- Everglades Biopharma LLC
- Exonate Ltd
- EyeGate Pharmaceuticals Inc
- EyeGene Inc
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Gene Signal International SA
- GlaxoSmithKline Plc
- Graybug Vision Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Isarna Therapeutics GmbH
- Kalvista Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Kubota Vision Inc
- Kuur Therapeutics Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- Momenta Pharmaceuticals Inc
- NeuMedics Inc
- Novartis AG
- Novelty Nobility Inc
- Noveome Biotherapeutics Inc
- OccuRx Pty Ltd
- Ocugen Inc
- Ocular Therapeutix Inc
- Oculis SA
- OcuNexus Therapeutics Inc
- Opthea Ltd
- Outlook Therapeutics Inc
- Oxurion NV
- Pfizer Inc
- Phanes Therapeutics Inc
- PharmAbcine Inc
- Pleryon Therapeutics Ltd
- Profarma
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- RemeGen Ltd
- Rezolute Inc
- RiniSight Inc
- Ripple therapeutics Corp
- SciFluor Life Sciences LLC
- Semathera Inc
- Senju Pharmaceutical Co Ltd
- Suzhou Stainwei Biotech Inc
- Targeted Therapy Technologies LLC
- Verseon Corp
- Xbrane Biopharma AB
- YD Life Science Co
